Rigorous biomarkers for CDK7i response, including CDK7 expression (31, 86) and possibly the extent of basal CIN, should facilitate patient selection if these drugs enter clinical practice. The gene discussed is CDK7; the disease is cervical squamous intraepithelial neoplasia.